What does Norris Medicines do?

Norris Medicines Ltd is a micro-cap company in the Trading & Distributors industry, specializing in the manufacture of non-sterile and sterile dosage forms. As of March 2025, it reported net sales of 3 Cr and a market cap of Rs 20 Cr.

Overview:<BR>Norris Medicines Ltd is a micro-cap company in the Trading & Distributors industry, specializing in the manufacture of non-sterile and sterile dosage forms, including tablets, capsules, liquid orals, and injectable ampoules and vials.<BR><BR>History:<BR>Norris Medicines Ltd was established in September 1990 and was converted into a Public Limited Company on March 7, 1992. The company commenced commercial production in November 1991 and has reported net sales and profit for the quarter ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: Rs 20 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.50<BR>- Return on Equity: 8.64%<BR>- Price to Book: -1.35<BR><BR>Contact Details:<BR>- Address: Plot No 801/P & 802, GIDC Industrial Estate Ankleshwar Gujarat : 393002<BR>- Tel: 91-2646-223462/227530<BR>- Email: secretarial@norrispharma.com<BR>- Website: http://www.norrispharma.com

Who are in the management team of Norris Medicines?

As of March 2022, the management team of Norris Medicines consists of Vimal D Shah as Managing Director and Hiten Parikh, S A M Azmathullah, and Susmita Mahapatra as Independent Directors.

As of March 2022, the management team of Norris Medicines includes the following individuals:<BR><BR>1. Vimal D Shah - Managing Director<BR>2. Hiten Parikh - Independent Director<BR>3. S A M Azmathullah - Independent Director<BR>4. Susmita Mahapatra - Independent Director<BR><BR>Vimal D Shah is the Managing Director, while the other three members serve as independent directors.

Has Norris Medicines declared dividend?

No Dividend History Available

Is Norris Medicines overvalued or undervalued?

As of April 25, 2023, Norris Medicines is considered risky and overvalued due to its negative PE ratio of -16.05 and poor financial metrics compared to competitors, despite a recent stock performance that outpaced the Sensex.

As of 25 April 2023, the valuation grade for Norris Medicines has moved from does not qualify to risky, indicating significant concerns regarding its financial health. The company appears to be overvalued, given its negative PE ratio of -16.05, a Price to Book Value of -1.39, and an EV to EBIT of -41.46. These ratios highlight severe profitability and valuation issues compared to its peers.<BR><BR>In comparison to industry competitors, Norris Medicines' metrics starkly contrast with those of Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25, and Cipla Ltd., with a PE ratio of 22.99. The significant disparity in these ratios suggests that Norris Medicines is not only underperforming but also carries a higher risk profile. While the stock has outperformed the Sensex over the past year with a return of 66.24% compared to the Sensex's 7.55%, the underlying financial metrics indicate that the current valuation does not justify this performance, reinforcing the conclusion of being overvalued.

What is the technical trend for Norris Medicines?

As of June 5, 2025, Norris Medicines shows a mildly bullish trend supported by bullish MACD and KST indicators, although daily moving averages indicate caution in the short term.

As of 5 June 2025, the technical trend for Norris Medicines has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, supporting the positive shift, while the monthly MACD also confirms this bullish stance. The Bollinger Bands indicate a mildly bullish trend on both weekly and monthly time frames. The KST is mildly bullish weekly and bullish monthly, further reinforcing the upward momentum. However, daily moving averages remain mildly bearish, which suggests caution in the short term. Overall, the current stance is mildly bullish, driven primarily by the MACD and KST indicators.

Why is Norris Medicines falling/rising?

As of 10-Jun, Norris Medicines Ltd is experiencing a price increase to 19.74, reflecting a 2.07% upward change. Despite strong annual returns and positive technical trends, the company faces challenges such as negative book value, high debt levels, and declining sales, indicating potential risks ahead.

As of 10-Jun, Norris Medicines Ltd is experiencing a price increase, currently at 19.74, reflecting a change of 0.4 or 2.07% upward. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive technical trend. Additionally, the stock has outperformed its sector by 1.55% today, and there has been a significant rise in investor participation, with delivery volume increasing by 73.44% compared to the 5-day average. Over the past year, Norris Medicines has generated an impressive return of 71.21%, significantly outperforming the market benchmark, which has only returned 6.22%. However, the company faces challenges, including a negative book value and weak long-term fundamental strength, as evidenced by declining net sales and operating profits over the past five years.<BR><BR>In the broader market context, while Norris Medicines has shown strong performance over the past year, its recent short-term return of -3.00% over the last week contrasts with the Sensex's gain of +2.05%. This divergence suggests that despite the stock's overall bullish trend, it has faced some recent headwinds. The company's high debt levels and negative EBITDA further contribute to its risk profile, indicating that while the stock may be currently rising, underlying financial weaknesses could pose challenges ahead.

Who are the peers of the Norris Medicines?

Norris Medicines' peers include Mihika Industrie, Regent Enterprises, NMS Global, Yash Management & Sat., AA Plus Trade, Shyam Telecom, Muller & Phipps, Dalmia Industria, Sumeru Industrie, and Diggi Multitrade. While Norris Medicines has a 1-year return of 33.84%, its peers generally show below-average management and growth risks, with negative returns for several.

Peers: The peers of Norris Medicines are Mihika Industrie, Regent Enterp., NMS Global, Yash Mgmt & Sat., AA Plus Trade, Shyam Telecom, Muller & Phipps, Dalmia Industria, Sumeru Industrie, and Diggi Multitrade.<BR><BR>Quality Snapshot: Below Average management risk is observed at Mihika Industrie, Regent Enterp., NMS Global, Yash Mgmt & Sat., AA Plus Trade, and Diggi Multitrade, while Average management risk is found at none. Management risk does not qualify for Norris Medicines, Shyam Telecom, Muller & Phipps, Dalmia Industria, and Sumeru Industrie. Average growth is noted at Mihika Industrie, Regent Enterp., Yash Mgmt & Sat., and the rest have Below Average growth, including NMS Global, AA Plus Trade, and Diggi Multitrade. Growth does not qualify for Norris Medicines, Shyam Telecom, Muller & Phipps, Dalmia Industria, and Sumeru Industrie. Excellent capital structure is present at Regent Enterp. and Yash Mgmt & Sat., while Below Average capital structure is seen at Mihika Industrie, NMS Global, AA Plus Trade, and Diggi Multitrade, with the rest not qualifying.<BR><BR>Return Snapshot: NMS Global has the highest 1-year return at -37.96%, while AA Plus Trade has the lowest at -71.95%. Norris Medicines has a 1-year return of 33.84%, which is significantly higher than both. Additionally, peers such as Mihika Industrie, Regent Enterp., AA Plus Trade, and Diggi Multitrade have negative six-month returns.

Who are the top shareholders of the Norris Medicines?

The top shareholders of Norris Medicines are Vimal D Shah, the promoter with 23.6%, and Fab Metals Private Limited, the largest public shareholder with 41.99%. Individual investors hold 20.76%, while mutual funds hold a minimal 0.01%, and there are no foreign institutional investors or pledged promoter holdings.

The top shareholders of Norris Medicines include Vimal D Shah, who is the promoter with the highest holding at 23.6%. Additionally, Fab Metals Private Limited is the highest public shareholder, holding 41.99%. Individual investors collectively hold 20.76% of the shares. There are also two mutual fund schemes that hold a very small percentage (0.01%), while there are no foreign institutional investors (FIIs) involved. Notably, there are no pledged promoter holdings.

How big is Norris Medicines?

As of 24th July, Norris Medicines Ltd has a market capitalization of 16.00 Cr and reported Net Sales of 5.82 Cr with a Net Profit loss of 1.24 Cr for the latest four quarters. As of March 2024, Shareholder's Funds were at a loss of 13.63 Cr, while Total Assets were valued at 13.22 Cr.

As of 24th July, Norris Medicines Ltd has a market capitalization of 16.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 5.82 Cr. However, it experienced a Net Profit loss of 1.24 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where Shareholder's Funds stood at a loss of 13.63 Cr, while Total Assets were valued at 13.22 Cr.

When is the next results date for Norris Medicines?

Norris Medicines will declare its results on 14 November 2025.

Norris Medicines will declare its results on 14 November 2025.

Are Norris Medicines latest results good or bad?

Norris Medicines' latest results are unfavorable, showing a 46.32% decline in net sales and a 34.78% drop in net profit compared to the previous quarter, leading to a 'Strong Sell' rating from MarketsMOJO. Stakeholders should monitor the company's future developments closely.

Norris Medicines' latest results for the quarter ending June 2025 indicate a challenging performance. The company experienced a significant decline in net sales, with a decrease of 46.32% compared to the previous quarter. Additionally, standalone net profit also fell by 34.78%. This downward trend is concerning, especially given that the previous quarter had shown positive growth.<BR><BR>The overall financial performance has remained flat, and the unchanged financial score over the last three months suggests a lack of improvement. The market sentiment surrounding Norris Medicines is currently negative, as reflected by the 'Strong Sell' rating issued by MarketsMOJO. The trading and distribution sector is facing various challenges, and Norris Medicines' results seem to reflect these broader industry trends.<BR><BR>In summary, the latest results are not favorable for Norris Medicines, indicating a need for stakeholders to closely monitor the company's future developments and market positioning.

How has been the historical performance of Norris Medicines?

Norris Medicines has shown a declining trend in net sales and profitability, with net sales dropping from 12.25 Cr in Mar'21 to 5.82 Cr in Mar'25, and consistent losses reported, including a profit after tax of -1.24 Cr in Mar'25. The company's financial distress is further highlighted by a deteriorating book value per share of -14.98 and stagnant cash flow from operating activities.

Answer:<BR>The historical performance of Norris Medicines shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Norris Medicines has experienced a downward trajectory in net sales, decreasing from 12.25 Cr in Mar'21 to 5.82 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 16.27 Cr in Mar'19 to 5.82 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 13.99 Cr in Mar'21 to 6.08 Cr in Mar'25, yet the operating profit (PBDIT) remained negative, with a loss of -0.20 Cr in Mar'25 compared to a profit of 0.93 Cr in Mar'23. Profit before tax has consistently been negative, culminating in a loss of -1.18 Cr in Mar'25. The profit after tax also reflected losses, amounting to -1.24 Cr in Mar'25, indicating persistent financial challenges. The company's total liabilities stood at 12.91 Cr in Mar'25, with total debt slightly increasing to 21.58 Cr. The book value per share has deteriorated to -14.98 in Mar'25, highlighting the company's financial distress. Cash flow from operating activities has been stagnant, with no cash inflow reported in recent years, further emphasizing the company's ongoing struggles.

Should I buy, sell or hold Norris Medicines?

Which are the latest news on Norris Medicines?